Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome "EMISO"

Not yet recruiting

Phase 3 Results N/A

Trial Description

The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.

Conditions

Interventions

  • Memantine (Ebixa)Drug
    Intervention Desc: Beside the usual treatment for ischemic stroke this group will be treated by memantine.
    ARM 1: Kind: Experimental
    Label: Memantine
    Description: Patients with ischemic stroke in MCA territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
  • Placebo Drug
    Intervention Desc: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
    ARM 1: Kind: Experimental
    Label: Placebo
    Description: Patients with ischemic stroke in MCA territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary Investigation of neurological deficit by NIHSS(National institute of health scale score) 7 days No
Primary Investigation of disability by mRS(modified Rankin scale) 7 days No
Secondary Investigation of neurological deficit by NIHSS 28 days No
Secondary Investigation of disability by mRS 28 days No
Primary Investigation of neurological deficit 7 days No
Primary Investigation of disability 7 days No

Sponsors